Menu

Rothwell Figg BiosimilarIP Blog

Skip navigation Menu
  • Regulatory
  • Legal
  • News
  • About RFEM
  • Search

PGR

Random entry RSS

You are here:

  1. Home
  2. Tag Archives: PGR
  • Posted in:

    • Legal

    PGR Instituted for Protein Refolding Patent

    By Nicole DeAbrantes May 23, 2019 Comments are off

    Recently, in Adello Biologics LLC v. Amgen Inc., Case PGR2019-00001 (Paper No. 13) (PTAB Apr. 19, 2019), the PTAB instituted...

    Read more

    Tagged with: Adello Biologics, Amgen, Apotex, BPCIA, Featured, PGR, PTAB

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Eli Lilly Files PGR Petition against Genentech’s IL-17A/F Heterodimer Patent

    By Caitlin M. Wilmot April 17, 2019 Comments are off

    On April 2, 2019, Eli Lilly and Company (“Lilly”) filed a Petition for Post-Grant Review (“PGR”) of Genentech’s U.S. Patent...

    Read more

    Tagged with: Eli Lilly, Genentech, News, PGR, PTAB

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • Legal

    New Proposed Legislation: The Hatch-Waxman Integrity Act of 2018

    By Nicole DeAbrantes July 3, 2018 Comments are off

    On June 14, 2018, Senator Orrin Hatch of Utah, the co-author of the Hatch-Waxman Act, filed an amendment to the Hatch-Waxman Act in an...

    Read more

    Tagged with: ANDA, BPCIA, FDA, IPR, Legal, PGR

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

Sign Up for Updates

Don’t worry. We don’t spam.

Practice Contacts

  • E. Anthony Figg

  • Joseph A. Hynds

  • Seth Cockrum

Featured Posts

  • U.S. – E.U. Mutual Recognition Agreement Will Reduce Costs

    August 1, 2019

  • House Democrats Seek to Remove Biologics Exclusivity Period From USMCA

    July 25, 2019

  • What Pharma Companies Must Do Globally to Benefit From Canada’s Patent Term Extension Framework

    July 22, 2019

Popular Tags

AbbVie adalimumab Amgen Avastin® bevacizumab Biocon Biogen Boehringer Ingelheim BPCIA Celltrion District Court EMA FDA Featured Federal Circuit Genentech Herceptin® Hospira Humira® Infliximab IPR Janssen Legal Litigation Mylan Neulasta® News Notice Requirement Patent Dance pegfilgrastim Pfizer PTAB Regeneron Regulatory Remicade® Rituxan® Rituximab Roche Samsung Bioepsis Sandoz Sanofi Supreme Court Teva trastuzumab USPTO
Opinions expressed in articles on www.BiosimilarsIP.com are solely those of the author only and do not necessarily reflect the views of Rothwell Figg Ernst & Manbeck, P.C., its clients, or any of its respective affiliates. These materials are for general information purposes only and should not be taken as legal advice per the full disclaimer below.

Contact Us

Email Us
202.783.6040
Our Location

Find Out More

  • About Us
  • Results
  • Careers
  • Practices
  • Publications
  • News & Events
  • Professionals

© 2019 Rothwell, Figg, Ernst & Manbeck, P.C. All Rights Reserved

  • Disclaimer
  • Privacy Policy
Back to Top